Geneva, Oct. 9 -- International Clinical Trials Registry received information related to the study (ChiCTR2600133335) titled 'Clinical Validation of Life's Essential 8 (LE8) for Identifying High MAF-5 Liver Fibrosis Risk in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease' on Sept. 24.
Study Type: Observational study
Study Design:
Cross-sectional
Primary Sponsor: Shanghai Tongren Hospital
Condition:
Metabolic dysfunction-associated steatotic liver disease (MASLD) and its related high liver fibrosis risk state.
Recruitment Status: Not Recruiting
Phase: N/A
Date of First Enrollment: 2026-10-01
Target Sample Size: MASLD Clinical Validation Cohort:300;
Countries of Recruitment:
China
To know more, visit h...